Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA
ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...
reimbursement
Advertisement
CVRx Secures Category I CPT Codes for Barostim Therapy
MINNEAPOLIS | January 6, 2026 — CVRx, Inc. has announced the implementation of new Category I Current Procedural Terminology...
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
Health Canada Approves Bylvay for Cholestatic Pruritus in ALGS
OTTAWA, Canada, September 9, 2025 — Health Canada has granted approval to Bylvay™ (odevixibat) for the treatment of cholestatic...
FDA TRG Classifies Five Amniotic Membrane Allografts as HCT/Ps
PHOENIX, August 28, 2025 — Five amniotic membrane allograft products have received official recognition from the FDA’s Tissue Reference...
Advertisement
